A new cancer drug may be able to inhibit both tumor growth and the spread of aggressive prostate cancer. This is shown in a ...

Blue Earth Therapeutics, a clinical-stage radiopharmaceutical company and University College London (UCL) today announced initiation of a Phase 1 clinical trial (NCT07414940) evaluating Actinium ...

For Gary Buchanan, pickleball is more than a game; it's a place where, for a few hours, he can set aside the reality of living with stage 4 cancer.

FDA concurrence supports US launch of a 2:1 randomized ~490-patient phase 3 comparing TLX591-Tx plus SOC versus SOC in ...

Novartis manufacturers Pluvicto which benefits men with advanced prostate cancer, and oncologists have told the HSE that ...

Hope for men with high-risk non-metastatic hormone resistant prostate cancerBy Dr Jacqueline Schmitt - Manager, Research ...

Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time.

Scientists at the University of Illinois Chicago have turned an unlikely source into a potential new weapon against cancer: ...

Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...

Federal officials may remove warnings on testosterone therapy drugs about heart and prostate risks, which could expand access ...

Development is moving to phase 2 LEGION-100-2a (NCT06533644) across global sites, with planned neoadjuvant prostate studies and expansion concepts in multiple solid tumors. Metastatic ...